Zymeworks Inc represents values of innovation, collaboration, and scientific excellence. As a biopharmaceutical company, Zymeworks is committed to developing breakthrough therapies to improve the lives of patients. The company's corporate philosophy revolves around leveraging its proprietary drug discovery platform and advanced protein engineering capabilities. By focusing on developing multifunctional therapeutics, Zymeworks aims to address unmet medical needs and deliver transformative treatments in oncology and other disease areas. With a strong emphasis on research and development, Zymeworks strives to revolutionize the field of biotechnology and contribute to advancements in patient care.

Zymeworks Inc is primarily present in several countries and regions. As a global biopharmaceutical company, Zymeworks operates in the United States, Canada, and Europe. With its headquarters based in Vancouver, Canada, Zymeworks has expanded its presence in major pharmaceutical markets, including the United States and various European countries. Being renowned for its innovative drug discovery and development technologies, Zymeworks has established collaborations with partners worldwide, contributing to its international presence and reach within the biopharmaceutical industry.

Zymeworks Inc, a leading biopharmaceutical company, has achieved numerous significant milestones. Over the years, the company has successfully advanced its proprietary Azymetric™ and EFECT™ platforms, revolutionizing the development of bispecific antibodies for various therapeutic areas. Some notable achievements include the partnership with leading pharmaceutical companies, such as Merck and Eli Lilly, for the development of multiple therapies. Zymeworks Inc has also received regulatory approvals and achieved clinical development milestones for its investigational drugs, showcasing its dedication to improving patient care. These milestones underline Zymeworks Inc's commitment to innovation and its relentless pursuit of breakthrough treatments in the field of biopharmaceuticals.

Zymeworks Inc, a leading biopharmaceutical company, was founded in 2003 in Vancouver, Canada. The company specializes in the development of innovative, protein-based therapeutics for the treatment of cancer and other diseases. With a strong focus on antibody engineering, Zymeworks has developed proprietary platforms that enable the design and optimization of therapeutic antibodies. Over the years, Zymeworks has established collaborations with global pharmaceutical companies, leveraging its technology to advance drug discovery and development efforts. With a dedicated team of experts and a robust pipeline of potential therapies, Zymeworks Inc continues to make significant contributions to the field of biopharmaceuticals.

The main competitors of Zymeworks Inc in the market include large pharmaceutical companies such as Amgen, Roche, Novartis, and Bristol-Myers Squibb. These companies are also actively involved in the field of biotechnology and drug development.

Zymeworks Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Zymeworks Inc is focused on the development of multifunctional biotherapeutics using its proprietary Azymetric™ and EFECT™ platforms. The company leverages these platforms to create novel antibody-based drug candidates with enhanced characteristics, such as increased potency and multi-targeting capabilities. Zymeworks aims to address unmet medical needs across various therapeutic areas, including oncology, autoimmune, and inflammatory diseases. By employing its innovative platforms, Zymeworks aims to bring differentiated and effective treatments to patients, while also collaborating with leading biopharmaceutical companies to advance its pipeline.

Zymeworks Коефіцієнт P/E становить -10,76.

Коефіцієнт виручки від продажу Zymeworks становить 7,77.

АлеАкції індекс якості для Zymeworks складає 3/10.

очікувана Zymeworks обсяг продажів становить 111,17 млн. USD.

очікувана Zymeworks прибуток становить -80,29 млн. USD.

Zymeworks Inc specializes in developing therapeutics for patients with cancer and immune disorders. The company aims to transform the treatment of these patients by using innovative technologies and science to create tailored and precise solutions for their needs. Zymeworks' business model consists of two main divisions - therapeutic development and biotechnology platform development. The company offers various products and services within these divisions. Therapeutic development focuses on developing an innovative oncology portfolio of novel multi-specific antibody fragments. The company's therapeutic products aim to precisely recognize and destroy cancer cells. Currently, the company is working on the development of 6 lead candidates in the preclinical and clinical development phase. An example of this is Novartis' leading product, Kymriah®, which was developed in collaboration with Zymeworks. This product has been approved by the FDA and is now a widely used treatment for specific types of cancer. Platform development involves the artificial evolution of proteins to develop biopharmaceuticals with specific properties in a technically sophisticated manner. Zymeworks' product range is diverse and continuously expanding. In platform development, Zymeworks provides access to various biopharmaceutical expertise, such as protein engineering, fusion design, high-throughput screening, and animal modeling. Building on comprehensive experience and recognized capabilities in protein engineering design, Zymeworks offers a full spectrum of common and innovative biopharmaceutical development technologies. In conclusion, Zymeworks Inc is a company committed to improving the quality of life for patients with cancer and immune disorders. The company is active in therapeutic development through the development of novel multi-specific antibody fragments in the preclinical and clinical development phases. Platform development involves the artificial evolution of proteins to develop biopharmaceuticals with specific properties. The company offers a variety of products and services that are continuously expanding and supports its customers in the development of new and innovative medications. Answer: Zymeworks Inc specializes in developing therapeutics for cancer and immune disorders using innovative technologies and science. They have two main divisions - therapeutic development and biotechnology platform development. They offer various products and services in these areas.

Zymeworks виплачує дивіденд у розмірі 0 USD, розподілений на виплати протягом року.

Дивіденди для Zymeworks на даний момент не можуть бути розраховані, або компанія не виплачує дивіденди.

ISIN Zymeworks є CA98985W1023.

WKN Zymeworks становить A2DP0F.

Тікер Zymeworks це ZYME.

Протягом останніх 12 місяців компанія Zymeworks виплатила дивіденд у розмірі . Це відповідає приблизній дивідендній дохідності . Очікується, що протягом наступних 12 місяців Zymeworks виплатить дивіденд у розмірі 0 USD.

Дивідендна дохідність Zymeworks наразі становить .

Zymeworks виплачує дивіденди щоквартально. Вони виплачуються у місяцях .

Zymeworks протягом останніх 0 років щороку виплачував дивіденди.

На наступні 12 місяців очікується дивіденди у розмірі 0 USD. Це відповідає дивідендній дохідності 0 %.

Zymeworks призначається до сектора "Здоров'я".

Щоб отримати останній дивіденд від Zymeworks від 01.10.2024 у розмірі 0 USD, тобі потрібно було мати акцію в портфелі до дня Ex-Tag 01.10.2024.

Останню дивіденду було виплачено 01.10.2024.

У 2023 році компанія Zymeworks виплатила 0 USD у вигляді дивідендів.

Дивіденди Zymeworks виплачуються у USD.